1. Market Research
  2. > Pharmaceutical Market Trends
Lumakras Drug Clinical Insight & Sales Forecast 2026

Lumakras Drug Clinical Insight & Sales Forecast 2026

  • July 2021
  • 60 pages
  • ID: 6105452
  • Format: PDF
  • Kuick Research

Summary

Table of Contents

“Lumakras Drug Clinical Insight & Sales Forecast 2026” Report Highlights:
• NSCLC Targeting Lumakras Market Opportunity (US$ Million)
• Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million)
• Pharmacokinetics of Lumakras (Sotorasib)
• Dosage, Patent & Price Analysis
• Lumakras Ongoing Clinical Trials
• Global KRAS Protein Inhibitors Clinical Trials

The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management of cancer. Despite huge advancements in the field of cancer therapeutics, there has been no permanent cure of cancer till now. However, the advancement in the field of science and technology has led to the identification of potential targets which can be utilized in drug development process.

The identification of Kirsten rat sarcoma viral oncogene homolog (KRAS) gene as well as its potential role in the pathogenesis and proliferation of cancer has shown to be boon in cancer therapeutics. The extensive research and development by the researchers has led to the discovery of novel KRAS inhibitors which are used in the management of rare ALK positive cancers. Till now, only one KRAS inhibitor has been approved for the management of non-small cell lung cancer.

Lumakras (Sotorasib) is first KRAS inhibitor developed by Amgen and was approved by FDA in May, 2021. Lumakras is a once-daily oral prescription medicine used to treat adults living with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment for their cancer. The approval of Lumakras represents as one of the major revolution in the field of cancer treatment.

Owing to their favorable characteristics in management of NSCLC as well its high specificity and efficacy, it is expected that Lumakras market will witness high growth rates. As per report findings, it is expected that Lumakras market is expected to surpass US$ 1.5 Billion by 2026. This is due to the ability of Lumakras in overcoming the limitations of already conventional cancer therapies. Moreover, the drug Lumakras is not associated with side effects in comparison to conventional cancer treatments and also improved the survival rates in patients.

Although the market is poised to growth in coming years but several factors limits their growth in market. The high cost of cancer therapy is one of the major limiting factors which will restrict the growth of market in coming years. However, increasing initiatives by government and the pharmaceutical companies for the development of favorable reimbursement policies will help in lowering the cost of the therapy, thus reducing financial toxicity on patients.

The global Lumakras market will follow trajectory path during the forecast period owing to the single product approval. In addition to this, researchers are also evaluating the role of Lumakras in other solid tumors as well in combination of other immunotherapeutic drugs, which will drive the growth of market. North America particularly US is expected to dominate the global Lumakras market for next few years owing to increase in prevalence of non-small cell lung cancer and the presence of large pharmaceutical companies which actively indulge in research and development activities.

The report global Lumakras market contains information on the price, dosage and expected sales of the drug in different regions. In addition to this, it also provides information on the safety, efficacy, pharmacokinetics, and pharmacovigilance profile of Lumakras. The report also provides insights on the recent clinical trials undergoing with the drug and predict the future market of the drug at a global level.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

High Potency Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report By Product, By Manufacturer Type, By Drug Type, By Application, By Region And Segment Forecasts, 2021 - 2028

  • $ 5950
  • September 2021
  • 140 pages

High Potency Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report By Product (Synthetic, Biotech), By Manufacturer Type (In-house, Outsourced), By Drug Type, By Application, By ...

  • World
  • APAC
  • Pharmaceutical
  • Biotechnology
  • Industry analysis
  • Cancer Mortality
  • Smoking Prevalence

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on